Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia

TO THE EDITOR:

Acute myeloid leukemia (AML) is the most common acute leukemia in adults and its prevalence significantly increases in older patients.¹ Furthermore, while the 5-year rate of overall survival (OS) for adults younger than 60 is around 40%, it decreases to 10% in patients above this age.² The treatment landscape of AML is evolving from a curative/intensive vs palliative/low-intensity binary approach into new strategies that incorporate mutation-specific targeted therapies, apoptosis-inducing small molecules, and immunotherapy.³ Nonetheless, older patients who are unable to receive intensive chemotherapy with acceptable side effects⁴ and patients with relapsed/refractory disease⁵ continue to have dismal survival rates. Thus, the identification of new targets and treatment modalities is an unmet need.

The use of anti-CD38 monoclonal antibodies has significantly prolonged the OS of patients with multiple myeloma (MM). Accordingly, daratumumab^6-10 and isatuximab^11,12 are approved for the treatment of newly diagnosed and relapsed/refractory disease. In AML, there are limited data about the potential role of CD38 as a therapeutic target,^13-15 with virtually no information about CD38 levels in older patients.¹⁶ Thus, here we analyzed the frequency and pattern of CD38 expression in patients with AML ineligible to receive intensive chemotherapy and performed preclinical studies to investigate the antitumor efficacy of 2 CD38-targeting antibodies, isatuximab and a novel CD38/CD3 × CD28 trispecific T-cell engager (CD38-TCE).

A complete description of methods and techniques used in this study is available in supplemental Data. Briefly, CD38 expression was evaluated using EuroFlow standardized operating procedures^17,18 in bone marrow (BM) aspirates from 241 newly diagnosed patients with AML with a median age of 75, who were enrolled in the PETHEMA-FLUGAZA phase 3 clinical trial.¹⁹ Preclinical studies were performed in BM aspirates from 25 patients with AML (median age, 70; range, 34-84). The KG-1, MOLM-13 and OCI-AML3 cell lines were used to investigate the mode of action and antitumor activity of 2 anti-CD38 antibodies, isatuximab and an experimental CD38-TCE (SAR442257, Sanofi R&D, Cambridge, MA).²⁰ Isotypes of each antibody lacking the CD38-binding domain were used as control. BM aspirates and peripheral blood mononucleated cells (PBMC) from age-matched healthy adults (n = 16) were used as control in preclinical studies. All samples were collected after informed consent was given by each participant, according to the local ethics committee and the Declaration of Helsinki.

Expression of CD38 was observed in 239 of the 241 (99.2%) older patients with AML (Figure 1A), of which homogeneous CD38 expression was observed in 134/241 (55.6%) and heterogeneous CD38 expression was observed in 105/241 (43.6%) of cases. Homogeneous CD38 expression was more frequent in patients with normal karyotype compared with altered karyotype (66/97 [68%] vs 53/117 [45%]; P = .001) and in those with favorable/intermediate cytogenetic risk compared with adverse cytogenetic risk according to the 2010 Medical Research Council criteria (98/156 [63%] vs 31/77 [40%]; P = .001). Nonetheless, the percentage of CD38⁺ tumor cells at diagnosis had no impact in OS (Figure 1B). In patients with paired samples, CD38 density in tumor cells did not decrease over time from diagnosis to the assessment of measurable residual disease (n = 10) or till relapse (n = 3), (Figure 1C-D; supplemental Figure 1). Altogether, these results demonstrate that CD38 is present in older patients with AML, although with lower density when compared with that observed in plasma cells from healthy adults (Figure 1E) and from patients with MM²¹ (data not shown).

Because the 2 anti-CD38 antibodies being investigated in this study induce tumor lysis through the respective binding and activation of natural killer (NK) and T lymphocytes,^20,21 the abundance of both cell types in the BM of older patients with AML was analyzed (n = 240). Based on semiautomated multidimensional flow cytometry immunophenotyping (Figure 1F), the presence of BM NK and T lymphocytes was noted in most patients at diagnosis (Figure 1G-H). Therefore, older patients with AML display immune effector cells in the primary site of tumor expansion that, together with the presence of CD38 in tumor cells described above, support the preclinical investigation of isatuximab and CD38-TCE.

Two AML cell lines with CD38 density comparable with that of patients with AML (MOLM-13 and OCI-AML3) and another with significantly lower CD38 levels (KG-1) were selected for preclinical studies. Treatment of AML cell lines and NK lymphocytes or monocyte-derived macrophages isolated from healthy adults (n = 3) with isatuximab (70 nM), enhanced antibody dependent cellular cytotoxicity and phagocytosis, respectively, particularly in the 2 cell lines displaying the highest CD38 density (Figure 2A-B). Furthermore, there was significant tumor lysis in BM aspirates from patients with AML (n = 17; P = .0002), specifically in those with homogeneous (median of 19.5%; P = .004) vs heterogeneous (median of 4%; P = .125) CD38 expression (Figure 2C). These results suggest that, similar to MM,²¹ the mode of action of isatuximab in AML might be influenced by CD38 levels (Figure 2D) and that patients with heterogeneous CD38 expression are less likely to respond to an anti-CD38 monoclonal antibody.

Leukemic cells with reduced CD38 expression could potentially be lysed by other immunotherapeutic modalities which are less dependent on the density of the target antigen, such as anti-CD38 chimeric antigen receptor T cells and T-cell engagers.^22-24 Thus, additional preclinical studies were performed with the CD38-TCE that includes an anti-CD28 costimulatory signal to enhance T-cell activation and increase tumor lysis at lower drug concentrations.²⁰ Indeed, treatment of MOLM-13 and PBMC from healthy adults (n = 6) with increasing concentrations of the CD38-TCE resulted in a significant expansion of CD69⁺ T lymphocytes, in contrast to the null effect of isatuximab (Figure 2E). Interestingly, treatment with the CD38-TCE also activated NK lymphocytes at a higher degree than isatuximab. Additional experiments with purified T or NK lymphocytes demonstrated that activation of NK lymphocytes induced by the CD38-TCE was likely a T-cell–dependent bystander effect (supplemental Figure 2).

The simultaneous activation of 2 effector cell types by the CD38-TCE could potentially result in greater tumor depletion when compared with isatuximab, which only activated NK lymphocytes. Accordingly, treatment of PBMC (n = 6) and MOLM-13 cells (effector-to-target cell ratio of 10:1) with isatuximab or the CD38-TCE (both 700 pM) for 48 hours, showed that tumor depletion was significantly higher with the latter (Figure 2F). Tumor depletion in some BM aspirates from patients with AML (n = 8) was observed with CD38-TCE, including leukemic cells from 2 cases that were resistant to isatuximab (Figure 2G). Conversely, tumor cells from 1 patient were sensitive to isatuximab and not to the CD38-TCE. Of note, the efficacy of the CD38-TCE was not significantly associated with CD38 expression in tumor cells and the antigen was not shed from the surface after binding (supplemental Figure 3).

There were no clinical (eg, age, disease stage, tumor burden) or immune (eg, effector-to-target cell ratio or frequency of BM neutrophils, monocytes, basophils, eosinophils, and NK, CD4⁺, CD8⁺, and B lymphocytes) features significantly associated with responsiveness to isatuximab or CD38-TCE (supplemental Figure 4). In addition, the percentage of CD28⁺ T lymphocytes in primary AML samples was not associated with the magnitude of tumor depletion induced by the CD38-TCE (supplemental Figure 5).

The percentages of immune cell types in BM aspirates from patients with AML remained unaltered after treatment with the CD38-TCE (Figure 2H). Thus, preclinical experimentation suggests that there was no apparent on-target off-tumor toxicity, which might be related with the median affinity (Kd = −20 nM) of anti-CD3ε and the monovalent CD28 binding.^20,25 As expected, normal CD34⁺ progenitors were undetectable in BM aspirates from patients with AML and on-target off-tumor toxicity could not be analyzed. In healthy adults, CD34⁺ progenitors display higher CD38 density than the immune cells in which no apparent on-target off-tumor toxicity was observed (supplemental Figure 6).

In summary, our results suggest a potential role for CD38 as a therapeutic target in AML. However, because not all patients express CD38 homogeneously and the density of the antigen is lower than that observed in other hematological malignancies such as MM, the immunotherapeutic modality would have to be tailored according to the pattern and levels of CD38 expression in tumor cells. Furthermore, the high CD38 density in CD34⁺ progenitors could suggest that treatment duration may require adaptation to mitigate the possibility of hematological adverse events, particularly with the CD38-TCE. Further in vivo studies are warranted to investigate this hypothesis.

Acknowledgments: The authors acknowledge all PETHEMA investigators involved in the FLUGAZA clinical trial: Manuel Mateo Pérez Encinas, Guillermo Debén Ariznavarreta, Lorenzo Algarra Algarra, Pascual Fernández Abellán, Susana Vives Polo, Olga Salamero, Amaia Balerdi Malcorra, Juan Miguel Bergua Burgués, Adriana Gascón Buj, Jorge Labrador, Josefina Serrano, Fernando Ramos Ortega, Esperanza Lavilla Rubira, María Ángeles Foncillas García, Pilar Herrera Puente, María del Pilar Martínez Sánchez, Alfons Serrano, Raúl Córdoba Mascuñano, Adriana Simiele Narvarte, Belén Vidriales, Mercedes Colorado Araujo, José Francisco Falantes González, Pau Montesinos Fernández, María del Mar Tormo Díaz, María José Sayas Lloris, Magdalena Sierra, Maite Olave Rubio, José Luis López Lorenzo, María Ángeles Fernández Fernández, Aránzazu Alonso Alonso, and María Lourdes Amador Barciela. The buffy coats used as a source of healthy adults’ PBMC were obtained from Navarra Blood and Tissue Bank/Navarrabiomed Biobank (Navarra Health Department).

This study was supported by the University of Navarra (Plan de Investigación Universidad de Navarra), the Centro de Investigación Biomédica en Red – Área de Oncología - del Instituto de Salud Carlos III (CB16/12/00369 and CB16/12/00489), the Instituto de Salud Carlos III/Subdirección General de Investigación Sanitaria (FIS No. PI16/01661), and the Scientific Foundation of the Spanish Association Against Cancer (FCAECC, INVES211176MART). This study was supported internationally by the Cancer Research UK, FCAECC and American International Recruitment Council under the Accelerator Award Program and by an independent grant from Sanofi.

Contribution: E.M.-S., T.J., B.P., and A.Z. conceived the idea and designed the study protocol; E.M.-S., T.J., C.S., B.P., and A.Z. analyzed flow cytometry data; E.M.-S., L.B., T.J., and A.Z. performed in vitro and ex vivo experiments; P.S.K., K.B., H.W., H.V.d.V., F.P., J.F.S.M., A.A., J.B., R.R.-V., S.V., D.M.-C., and P.M. provided study material and/or patients’ samples; E.M.-S. and A.Z. performed statistical analysis; E.M.-S., T.J., B.P., and A.Z. wrote the manuscript; and all authors reviewed and approved the manuscript.

Conflict-of-interest disclosure: B.P. reports honoraria for lectures from and membership on advisory boards with Amgen, Bristol Myers Squibb, Celgene, Janssen, Merck, Novartis, Roche, and Sanofi; unrestricted grants from Celgene, EngMab, Sanofi, and Takeda; and consultancy for Celgene, Janssen, Sanofi, and Takeda. The remaining authors declare no competing financial interests.

Correspondence: Bruno Paiva, Cancer Center Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Av. Pío XII 55, 31008 Pamplona, Spain; email: bpaiva@unav.es.